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Abstract
Obesity-related hypertension is associated with increased activity of the renin-angiotensin-
aldosterone system (RAAS), increasing arterial stiffness. Aerobic exercise decreases pulse wave 
velocity (PWV), therefore a treatment option for hypertension and obesity. Assess RAAS activity 
and PWV before and after 4 weeks of aerobic training in unmedicated, pre-to-stage-1 
hypertensives. Ten obese subjects (52±3.2 years, body mass index ¼ 33.5±1.4) performed 30 min of 
aerobic exercise on a treadmill 3 days per week at 65%of peak oxygen consumption (VO2peak). 
Descriptive characteristics, systolic and diastolic blood pressure (SBP and DBP), PWV, and a blood 
draw was performed at baseline, following the 4-week control and training interventions. No 
differences in descriptive characteristics during the control period were observed, however, a 
significant decrease in plasma aldosterone (ALDO) (255.4±75 to 215.8±66 pg ml  1, P ¼ 0.001), 
SBP (140±12 to 136±10.4 mm Hg; P ¼ 0.02), DBP (89±4.2 to 85±6.3 mm Hg; P ¼ 0.03) and central 
PWV (11.2±0.6 to 9.8±0.8 m s  1; P ¼ 0.04) was shown pre-to-post exercise training. Four weeks 
of moderate-intensity aerobic training in obese, hypertensives decreases plasma ALDO 
independently of body weight and is significantly correlated to decreases in PWV reductions.
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Obesity-related hypertension is associated with increased activity of the renin-angiotensin-aldosterone system (RAAS), increasing
arterial stiffness. Aerobic exercise decreases pulse wave velocity (PWV), therefore a treatment option for hypertension and obesity.
Assess RAAS activity and PWV before and after 4 weeks of aerobic training in unmedicated, pre-to-stage-1 hypertensives. Ten obese
subjects (52±3.2 years, body mass index¼ 33.5±1.4) performed 30 min of aerobic exercise on a treadmill 3 days per week at 65%
of peak oxygen consumption (VO2peak). Descriptive characteristics, systolic and diastolic blood pressure (SBP and DBP), PWV, and a
blood draw was performed at baseline, following the 4-week control and training interventions. No differences in descriptive
characteristics during the control period were observed, however, a significant decrease in plasma aldosterone (ALDO) (255.4±75
to 215.8±66 pg ml 1, P¼ 0.001), SBP (140±12 to 136±10.4 mm Hg; P¼ 0.02), DBP (89±4.2 to 85±6.3 mm Hg; P¼ 0.03) and
central PWV (11.2±0.6 to 9.8±0.8 m s 1; P¼ 0.04) was shown pre-to-post exercise training. Four weeks of moderate-intensity
aerobic training in obese, hypertensives decreases plasma ALDO independently of body weight and is significantly correlated
to decreases in PWV reductions.
INTRODUCTION
The incidence of obesity and hypertension is escalating rapidly in
the United States. Population data report that there has been a
doubling of obese individuals since 1980, with an increase in the
number of obese hypertensives presently at 41% of the
population.1 Moreover, research reports that hypertension is six
times more frequent in obese than in lean individuals.2,3 This
disconcerting synergism brings serious health related problems as
obesity-related hypertension causes hemodynamic alterations
through structural adaptations as well as metabolic mechanisms.4
It has been shown that compared with lean controls, obese
individuals report elevated plasma renin activity (PRA) as well as
angiotensin II (Ang II) and plasma aldosterone (ALDO) levels that
cause vasoconstriction, ions, water and sodium reabsorption
leading to further increases in blood pressure (BP).5 The higher
systemic blood volumes and consequent greater cardiac output
reported by obese hypertensives may lead to a concomitant
increase in peripheral resistance and related increases in pulse
wave velocity (PWV) inducing heart and vascular wall
remodeling.4,6 Therefore, the renin-angiotensin-aldosterone
system (RAAS) is an important mechanism regulating fluid
balance.
Clinical data report that attenuation of PRA through pharma-
cological blockade or weight loss has been shown to decrease
ALDO and consequently resting BP.7,8 Moderate-intensity aerobic
exercise is prescribed as a cornerstone therapy for the prevention
and treatment of obesity and hypertension.9 It has been shown
that physical activity can positively affect the vasculature, lowering
PWV and improving arterial distensibility reducing resting systolic
(SBP) and diastolic (DBP) blood pressure by B4 mm Hg after
only 4 weeks of moderate-intensity aerobic exercise.10 These BP
reductions are of major clinical significance as decreases in resting
BP of 3 mm Hg have been shown to reduce the incidence of stroke
and all-cause mortality by 3- and 7-fold, respectively.11 However,
there are no known studies linking the beneficial changes in the
RAAS with aerobic exercise training in pre-to-stage-1 unmedicated
hypertensive humans.
Therefore, the purpose of this original independent prospective
investigation was to elucidate the effect of moderate-intensity
aerobic exercise on PRA and plasma Ang II and ALDO as well as
pulse wave transit times in an unmedicated, pre-to-stage-1
hypertensive population.
MATERIALS AND METHODS
Subjects
Ten obese, unmedicated, pre-to-stage-1 hypertensive12 individuals (seven
males, three females) between 40 and 60 years of age were recruited
through local community physicians after they had been identified within
the last year with pre- (n¼ 4) or stage-1 essential hypertension (n¼ 6). The
inclusion criteria were: (1) no history of diabetes, coronary heart disease or
kidney disease; (2) being nonsmokers; and (3) not being on any
medications, including antihypertensives or anti-inflammatories as
identified by their physicians and by a health history questionnaire. Due
to the confounding influence of estrogen on cardiovascular measures, only
postmenopausal women (history 412 months of amenorrhea) not
currently under hormone replacement therapy were recruited. The
present study was approved by the Institutional Review Board and all
subjects gave written consent.
Experimental design
Subjects reported to the laboratory at 0700 hours for each of the three
visits: at the start of testing for baseline measures (BLs), at the end of the
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4-week, pre-training control period (Pre) and at the end of the 4-week
aerobic training period, post exercise training (Post). Subjects received
cardiovascular and peak oxygen consumption (VO2peak) evaluations
followed by fasted blood marker assessment at 0700 hours within 24 h
of the final exercise session.
All subject visits took place at the same time of day to minimize diurnal
influences on tested physiological parameters. Pre-testing started with a
manual BP assessment and then subjects were asked to rest quietly in the
supine position in a dimly lit room for 15 min. Next, PWV was recorded at
central and distal sites followed by an electrocardiogram (heart rate) and
beat-to-beat BP recordings for a period of 10 min. After the second
laboratory visit, each subject underwent a supervised, 4-week aerobic
training program. The training prescription was designed using the values
attained from the preliminary exercise testing sessions. Aerobic training
consisted of 30 min supervised treadmill exercise, 3 days per week at 65%
of their VO2peak. At the conclusion of 4 weeks, the subjects reported back
to the lab within 24 h of their last exercise session for post-measurements.
Each exercise training session was supervised by a trained exercise
physiologist and subject compliance was 100%.
Anthropometric and body composition assessment
Body mass and stature were measured using a beam scale and a
stadiometer to the nearest 0.5 kg and 0.5 cm, respectively. Body mass index
was calculated as weight (kg) divided by height (m) squared. Body
composition assessment was determined by a BodPod whole body
plethysmography test (BodPod, Life Measurement Inc., Concord, CA, USA).
Peak aerobic capacity
To assess peak oxygen consumption, a modified Balke protocol was
utilized as previously described.13,14 Briefly, subjects started the test
walking at a speed of 3 m.p.h. with a 0% grade for 3 min. Treadmill speed
was then increased until a comfortable pace was reached and held
constant as grade increased by 2.5% every 3 min until volitional fatigue
was reached. Heart rate was measured and recorded every minute
throughout the test using a Polar Heart Rate Monitor (Polar Electro Inc.,
Woodbury, NY, USA). Ratings of perceived exertion were also assessed at
the end of each 3-min step.15 Expired gases were analyzed using a Quark
b2 breath-by-breath metabolic system (Cosmed, Rome, Italy). Maximal
exercise effort was considered achieved when subjects met three of the
following four criteria: (a) no change in heart rate with a change in
workload; (b) a final rating of perceived exertion score of 17 or greater on
the Borg scale (scale 6–20); (c) an RER greater than 1.15; and (d) a ‘plateau’
(increase of no more than 150 ml) in oxygen uptake with an additional
incremental increase in workload.
Central and peripheral arterial stiffness
PWV measurements were acquired with two MD6 bidirectional transcu-
taneous Doppler probes (Hokanson, Bellevue, WA, USA) in accordance with
the guidelines from the Clinical Application of Arterial Stiffness Task Force
3 and as previously reported by our laboratory.14,16 Each subject was
monitored with an EKG (modified CM5) and heart rate data was gated in
phase with the PWV measurements and used as timing markers for PWV
identification. Central PWV measures were obtained from the left common
carotid artery to the left femoral artery. Distances from the carotid site to
the mid-point of the suprasternal notch were subtracted from the carotid-
to-femoral artery distance. Peripheral PWV measures were obtained from
the left femoral artery to the ipsilateral superior dorsalis pedis artery. The
distance between each PWV location was obtained with a tape measure
and recorded to the nearest millimeter.
Data were collected in real time by aligning the Doppler waveforms and
the ECG tracings on a computer screen (MP100, BioPac Systems, Santa
Barbara, CA, USA). All readings were stored and analyzed offline at a later
time. PWV was measured from the foot-to-foot flow wave velocity, whereas
the foot of the sound wave was identified as the point of systolic upstroke.
A minimum of 12 pulse contours were recorded and analyzed as the
distances between points and the time delay between proximal and distal
foot waveforms were calculated as distance (D) divided by the change in
time (m s 1). One blinded technician analyzed all the data. The intra-class
correlation coefficient for PWV calculated using both central and
peripheral sites on two separate days was 0.97.
Hemodynamic monitoring
Each subject underwent BP measurements in compliance with the World
Health Organization guidelines with the recruiting physician before
the start of the study. BP was determined as the average of three
measurements using a manual mercury sphygmomanometer and a
stethoscope (Korotkoff phases I and IV for SBP and DBP, respectively).
For the acquisition of BP during supine rest, one-minute averages were
recorded for 10 min with the subjects in a supine position and attached to a
beat-to-beat BP monitoring system via finger plethysmography (Finometer,
FMS, Amsterdam ZO, The Netherlands). The Finometer estimates brachial
BP using an integrated brachial BP cuff and reconstructs brachial BP
waveforms from finger arterial waveforms by applying an inverse transfer
function, a waveform filter, a level correction and a level calibration.17
Blood analyses
Blood samples for 17beta-estradiol (E2), PRA and plasma Ang II
measurements were collected in ice-cold vacutainer tubes containing
EDTA (ethylenediaminetetraacetic acid) to inhibit metalloproteases at the
following concentrations: 5 mM E2; and 25 mM EDTA for PRA and Ang II.
PRA was measured by radioimmunoassay (GammaCoat Plasma Renin
Activity, DiaSorin Inc., Stillwater, MN, USA) and was defined as the rate of
Ang I generated from endogenous substrate. A previous method was
optimized for Ang II recovery and stability.18 Plasma (0.5 ml) was recovered
by centrifugation (3000 g 20 min, 4 1C), diluted to 2 ml in phosphate
buffer (50 mM sodium phosphate, 1 mM EDTA, 0.25 mM thimerosal, 0.25%
BSA) containing peptidase inhibitors at above final concentrations and
extracted on a phenyl solid-phase cartridge (Agilent Technologies, Santa
Clara, CA, USA). After washing columns twice with water (1 ml), Ang II was
eluted with methanol (750ml). The dried eluant was resuspended in 500ml
enzyme immunoassay buffer (Cayman Chemical Co., Ann Arbor, MI, USA)
and Ang II was measured by enzyme immunoassay. Assay linearity was
between 125ml and 1 ml of plasma. Blood samples used for plasma ALDO
measurements were collected using the anticoagulant heparin (14.3 USP
units ml 1) and aldosterone was measured by radioimmunoassay (Coat-A-
Count Aldosterone, Diagnostic Products, Los Angeles, CA, USA). The limits
of detection of these assays (in pg ml 1) are: E2, 3; PRA, 25; Ang II, 2 and
ALDO, 25. The complete blood count panel was sent to Upstate Medical
University Laboratories (Syracuse, NY, USA) for analyses using coded
subject identification.
Statistical analysis
Student’s t-test was employed to determine if statistical differences existed
in the descriptive characteristics. A 1 3 (BL, Pre and Post) ANOVA with
repeated measures using SPSS v18 (Chicago, IL, USA) and if a significant
interaction was found, a Bonferroni correction was applied to all
dependent variables. To delineate the effects of BP on PWV, we divided
MAP into PWV and tested if the adjusted values were significantly different.
Significance was set at an alpha o0.05 and all data were reported as
mean±s.e.m.
RESULTS
The descriptive characteristics of the subjects were reported in
Table 1. All female subjects had E2 levels below 7.5 pg ml
 1, thus
confirming their postmenopausal status (o10 pg ml 1). All male
Table 1. Descriptive characteristics at baseline, pre and post 4 weeks
of aerobic training
Variable BL Pre Post
Age (years) 54.1±2.8 54.1±2.8 54.1±2.8
Height (m) 1.62±0.08 1.62±0.08 1.62±0.08
Weight (kg) 73±3.0 73.0±5.0 72.5±3.0
Fat % 43±4.96 42.85±4.89 42.96±4.95
Fat weight % 45±6.13 44.3±4.73 45.5±6
Lean weight % 58.89±5.3 58.85±5.37 59.7±5
BMI (kgm 2) 33.5±1.4 33.5±1.4 33.5±1.4
Abbreviations: BL, baseline measure; BMI, body mass index. Values are
mean±s.e.m.
and female subjects were in the pre- to-stage-1 hypertensive
range (Table 2) as defined by the Joint National Committee for the
Prevention, Detection, Evaluation and Treatment of High Blood
Pressure (JNC 7) criterion.12
Four weeks of aerobic exercise training did not affect body mass
index (Table 1) and blood panel analysis of sodium, potassium,
chloride, carbon dioxide, aniongap, calcium, blood urea nitrogen,
creatinine and plasma glucose pre-to-post training and between
BL and Pre conditions (Table 3). No significant differences were
found in any of the Pre and BL values, therefore, we used the Pre
values when making comparisons with Post values. Results
reported a significant reduction in ALDO (P¼ 0.04) between Pre
and Post conditions (Figure 1). No significant differences in PRA
and Ang II were found between all conditions examined (Table 2).
Four weeks of aerobic exercise resulted in a mean decrease of
4 mm Hg (SBP and DBP) (P¼ 0.042) (Table 2) and a significant
reduction in central PWV (P¼ 0.038, Figure 2) between Pre and
Post training. We employed a Pearson’s correlation to determine
the level of correlation between ALDO and PWV and BP changes
and found that ALDO was moderately correlated to PWV (r¼ 0.45)
yet weakly correlated to SBP decreases (r¼ 0.33). No significant
differences in PRA were detected between men and the age-
matched postmenopausal women at BL, Pre or Post; however,
when comparing Pre with Post, the PRA levels approached
significance (P¼ 0.08). Further, a Pearson’s correlation coefficient
between significant groups was employed to determine the level
of correlation.
DISCUSSION
The present study has shown that 4 weeks of aerobic training
decreased BP, central PWV and plasma ALDO without significant
decreases in body composition in unmedicated middle-aged men
and age-matched postmenopausal women. It is well known that
aerobic exercise confers a protective effect on cardiovascular
diseases in adults with concomitant reductions in BP and arterial
stiffness. In accordance with our study, previous researchers report
that 1–4 weeks of moderate-intensity aerobic training reduced
BP10,19 and markers of arterial stiffness, without associated
changes in aerobic fitness or body composition.20 Similar to our
findings, Kohno et al.21 found that individuals with elevated
baseline PRA and hypertension showed the greatest decreases in
BP after 3 weeks of moderate-intensity training. Conversely, there
is a lack of studies addressing RAAS reductions in an unmedicated,
hypertensive group following aerobic training. Jones and
colleagues (2007) reported that 6 months of aerobic training
lowered plasma ALDO without changes in BP and loss of intra-
abdominal fat in pre-hypertensive and hypertensive subjects;
however, unlike our study, some of their subject population was
treated pharmacologically.22 Interestingly, the significance of the
reduction in cardiovascular variables such as BP and PRA may
depend highly on the timing of data collection. Zhang et al.23 has
shown that 1–4 weeks of low-to-moderate-intensity leg ergometry
led to significant decreases in BP, PRA and Ang II, whereas data
collection of the same variables from weeks 4–10 showed a
plateau in these data. Taken together, this suggests that the
timing of data collection for exercise studies in individuals with
elevated BP is crucial to capture BP and hormone changes that are
unrelated to humoral factors and plasma volume changes.
It is well known that increases in plasma ALDO concentrations
lead to increases in PWV transit times within an adult hypertensive
population. This is likely a result of localized mineralocorticoid
receptor activity within the endothelium24,25 as a significant
association exists between serum ALDO and central PWV, but not
peripheral PWV measurements.26 This result may indicate that
ALDO is more influential in central pressure regulation than in
peripheral vascular beds which is congruent with current data
showing ALDO receptors more highly positioned in the large
conduit than in the muscular peripheral arteries decreasing the
influence of ALDO on the peripheral arteries.27
The substantial reduction in ALDO following aerobic exercise
training is the most significant finding of our study. Plasma ALDO
concentrations, along with PRA and plasma Ang II have been
reported to be higher in obese subjects when compared with a
leaner population.28 Overexpression of PRA and plasma ALDO is
common in obese subjects and elevated levels increase blood
volume and vascular resistance.5 At present, it has been shown
that elevated levels of ALDO are positively correlated with
increased aortic and arterial stiffness, resulting in deleterious
effects on large arteries.29 Matsui et al.29 has recently shown that
pharmacological treatment with thiazide diuretics significantly
correlated with decreases in plasma ALDO and aortic PWV in
hypertensive individuals. Exercise is a common therapy prescribed
to decrease obesity status and BP. Few studies exist regarding the
correlation of plasma ALDO on BP following exercise in an obese,
hypertensive population. Our study suggests reduced plasma
ALDO contributes independently to the reduction in SBP and DBP
and central PWV.
This is the first study to match such findings in an obese,
unmedicated hypertensive cohort. Using a wait-listed control
period increases the power of the study and also enables the
researchers to evaluate reliability of assays and measurements
while the subjects act as their own controls. It is well known that
weight loss is the primary reason for the reduction in PRA and
plasma ALDO, resulting in lowered extracellular volume, sympa-
thetic nervous system activity and improved insulin resistance.30,31
Exercise training has been shown to reduce both systolic and
diastolic BP in normotensive and hypertensive adults via changes
in body composition and weight loss.32,33 One study compared
racial differences in plasma ALDO and BP showing six months of
aerobic exercise moderately lowered plasma ALDO but not BP in a
medicated and unmedicated cohort.22 However, the investigators
reported a mean baseline BP below the hypertensive level, which
may have been resultant of the medications the individuals were
prescribed and body composition reductions. It is important to
note that our duration and intensity of exercise training did not
result in significant changes in body composition or plasma
volume. Our study is in congruence with Whelton et al.34 as they
showed BP reductions following aerobic training in both
normotensive and hypertensive subjects with minimal weight
loss. Combined with our results, these findings suggest that the
ALDO decrease following moderate-intensity aerobic exercise
training was independent of decreases in body weight. Previous
studies have indicated factors associated with weight loss as
mediation for improved vascular smooth muscle tone and artery
compliance.35 However, our blood analyses revealed no significant
alterations in PRA, Ang II or any other blood markers analyzed,
Table 2. Cardiovascular and metabolic parameters at baseline, pre
and post 4 weeks of aerobic training
Variable BL Pre Post
VO2peak
(ml kg 1min 1)
32.4±2.4 — 33.7±3.1
PRA (ngml 1 h 1) 0.979±0.16 0.845±0.11 0.592±0.10
Ang II (pgml 1) 934±190 933±177 931±107
SBP (mmHg) 140±10.3 140±12 136±10.4a
DBP (mmHg) 90±5.4 89±4.2 85±6.3a
HR (b.p.m.) 66±3 67.8±4.3 64.8±2.9
Abbreviations: Ang II, angiotensin II; BL, baseline measure; DBP, diastolic
blood pressure; HR, heart rate; PRA, plasma renin activity; SBP, systolic
blood pressure; VO2peak, peak oxygen consumption. Values are reported as
mean±s.e.m. aDenotes significance at Pp0.05.
reinforcing the assumption that decreased ALDO concentrations
was the main factor responsible for BP and PWV reductions.
Our study also revealed a trend in PRA (37% decrease,
P¼ 0.064) inhibition after moderate-intensity exercise training
whereas Martinelli et al.36 found no changes in PRA despite their
observed reductions in BP and PWV. They theorized insufficient
weight loss as the likely reason for not observing any changes.
Dubbert et al. (1994); however, reported that 10 weeks of aerobic
exercise lowered plasma catecholamines, PRA and arterial BP in
untreated hypertensive subjects. Their data analyses on SBP
changes were significantly correlated with changes in PRA, but not
with body fat, suggesting that the decrement in PRA was the
primary cause for lowered SBP.37 Our changes in PRA could be a
contributor to the decreases we realized in PWV and BP; however,
PRA decreased slightly after the baseline measurement and PWV
increased in the study group, suggesting a threshold may need to
be exceeded before PRA contributes to decreases in PWV or our
sample size was too small to distinguish between the changes
following BLs. In a post hoc calculation of sample size, an increase
of only two subjects would have given us enough power to
determine the differences in baseline and PRA differences.
Pharmacologic inhibition of angiotensin-converting enzyme has
been shown to benefit the endothelium in heart failure patients
by increasing NO bioactivity or by attenuating reactive oxygen
species, which prevents the interaction of superoxide anions
which serve to increase endothelial NO synthase expression and
activity.38 Aerobic exercise training has been shown to augment
the bioavailability of NO through increases in endothelial NO
synthase, leading to beneficial decreases in arterial resistance and
BP in normotensives and hypertensive individuals.39 However, it
has been suggested that adipocyte markers, specifically elevated
plasma leptin hormone, contribute to increased Ang II levels in an
obese population. Their study associates weight loss with
appreciable decreases in Ang II levels, which would confer
benefits of reduced arterial resistance, in turn lowering BP. As
aforementioned, our subjects did not change their body
composition as a result of the exercise training, which may
explain the insignificant change in Ang II levels. The variation in
our Ang II response may have been due to the genetic variability
in the modulation of Ang II due to the inter-individual influence of
genetic factors on plasma angiotensin and angiotensin-converting
enzyme activity.40 This suggests that moderate-intensity aerobic
exercise and the associated depressor response linked to Ang II,
obesity and hypertension may be realized only in those
individuals that are determined to be ‘responders’.
CONCLUSIONS
Independent of genetic factors, the relationship between obesity
and hypertension is not fully understood and current research
offers only speculation. Until now, the availability of literature with
analysis of ALDO concentrations in human hypertensive models
was not in existence. The present study has shown that
aldosterone is attenuated in unmedicated, pre-to-stage-1 hyper-
tensive individuals independently of body weight following 4
weeks of moderate-intensity aerobic training, resulting as the
main factor responsible for SBP, DBP and PWV reductions.
Therefore, this exercise practice may offer an alternative therapy
for obesity-complicated hypertension.
Table 3. Blood panel at baseline, pre and post 4 weeks of aerobic training
Variables BL Pre Post
Sodium (mgdl 1) 141.4±1.26 141.5±1.85 142.1±1.37
Potassium (mgdl 1) 4.0±0.13 4.1±0.12 4.2±0.15
Chloride (mgdl 1) 103.7±1.42 104.6.±1.65 104.9±1.97
Carbon dioxide (mgdl 1) 26.7±2.36 26.9±1.85 26.2±2.39
Aniongap (mgdl 1) 10.4±1.96 10.0±1.05 10.7±1.95
Serum calcium (mgdl 1) 9.1±0.29 9.1± 0.32 9.2±0.36
Blood urea nitrogen (mgdl 1) 16.2±2.15 16.3±2.63 15.8±2.44
Creatinine (mgdl 1) 0.86±0.12 0.88±0.09 0.86±0.12
Free calcium (mgdl 1) 293.2±2.82 294.3±1.64 295.0±3.33
Glucose (mgdl 1) 82.4±7.71 83.3±6.57 85.3±10.27
Hemoglobin (mgdl 1) 15.1±0.55 16.4±1.2 14.2±1.4
Hematocrit (mgdl 1) 43±0.8 44±1.1 42±2.2
Abbreviation: BL, baseline measure. Values are expressed as mean±s.e.
Figure 1. Plasma aldosterone (ALDO) levels at baseline (BL), before
(Pre) and after (Post) 4 weeks of aerobic training. Data are presented
as mean±s.e., *Pp0.05 from Pre to Post.
Figure 2. Central pulse wave velocity (PWV) at baseline (BL), before
(Pre) and after (Post) 4 weeks of aerobic training. Data are presented
as mean±s.e., *Pp0.05 from Pre to Post.
What is known about topic
 Hypertension is six times more frequent in obese than in lean
individuals.
 Compared with lean controls, obese individuals report elevated
plasma renin activity as well as angiotensin II and plasma aldosterone,
causing further increases in blood pressure.
What this study adds
 Four weeks of aerobic training decreased BP, central PWV and
plasma ALDO without significant decreases in body composition in
unmedicated middle-aged men and age-matched postmenopausal
women.
 The timing of data collection for exercise studies in individuals with
elevated BP is crucial to capture BP and hormone changes that are
unrelated to humoral factors and plasma volume changes.
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